about
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Cutaneous leishmaniasis in Cuban immigrants to Texas who traveled through the Darién Jungle, PanamaCutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning TravelersVisceral leishmaniasis during pregnancy: A rare case report from Greece.Infectious Diseases of Poverty in Children: A Tale of Two WorldsTreatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier.A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase.Parasitic diseases in travelers: a focus on therapy.Immunity to visceral leishmaniasis: implications for immunotherapy.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis.Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.In vitro leishmanicidal activities of sesquiterpene lactones from Tithonia diversifolia against Leishmania braziliensis promastigotes and amastigotes.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
P2860
Q28271849-1C006689-DE32-4CF9-A77C-140E931D9BF8Q30275257-A976175D-2292-4F88-B111-95DFB2D281BFQ34015961-42BD83B5-66D4-4575-A008-90973ABEF7EAQ35180338-033800FD-AAE6-4F0D-81B5-0ECDEBEF4090Q36282416-BC1A382C-3154-4FF3-BF91-381D15495690Q36328026-D4DA6C6B-6B9A-4209-BC55-E019741B16EAQ36450849-1231B6C6-C352-47B2-B20D-930B189B1A87Q37272354-5C07C79A-0651-4E5C-8EC5-3602B8FCC998Q38112776-90C26869-69C3-4FEC-93FC-2477E35170ACQ38192001-D66CF5DE-2E5E-4426-B2E1-AF1D8C1FA0C8Q38243220-4AD9D51B-1666-4868-AE0B-F78A786C7363Q38511211-9BCDE57A-B9CB-418F-B722-6CBB92E8F1C4Q39575305-92908F89-0C26-41A7-8E9C-15C7117CD184Q40479825-2A8D98D1-BBBC-4CA1-B86A-8D10C39BB98EQ42228007-28A8EC40-9512-43BA-B7AA-D8EE80A56A0CQ47548487-6069FD98-39BF-4B6E-87CD-8E20F74E1078Q50662423-7A1B73E9-BA2C-4758-A63A-1BFE9DBCB116Q54961274-52DFE3F6-644F-403B-93A6-2318255517E5
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Leishmaniasis in the United States: treatment in 2012
@ast
Leishmaniasis in the United States: treatment in 2012
@en
type
label
Leishmaniasis in the United States: treatment in 2012
@ast
Leishmaniasis in the United States: treatment in 2012
@en
prefLabel
Leishmaniasis in the United States: treatment in 2012
@ast
Leishmaniasis in the United States: treatment in 2012
@en
P2860
P1476
Leishmaniasis in the United States: treatment in 2012
@en
P2093
Henry W Murray
P2860
P304
P356
10.4269/AJTMH.2012.11-0682
P407
P577
2012-03-01T00:00:00Z